Active ingredientLazertinibCat. No. P-L027-001CAS 1903008-80-9Family · Pharmaceutical analytical standards
Lazertinib
An oral EGFR tyrosine kinase inhibitor for non-small cell lung cancer with EGFR mutations: it was approved in South Korea in 2021 and in the US in 2024, in combination with the antibody amivantamab. This family brings together the active ingredient and nitrosamines.
Did you know?It was born in South Korea from a project started in 2013, with a molecular design aimed at crossing the blood-brain barrier and hitting its target selectively: it is the 31st new drug developed in the country.
Go to the active ingredient →Active ingredientLazertinibCat. No. P-L027-001CAS 1903008-80-9
NitrosamineN-Nitroso Lazertinib Impurity 1Cat. No. P-L027-002
NitrosamineN-Nitroso Lazertinib Impurity 2Cat. No. P-L027-003
NitrosamineN-Nitroso Lazertinib Impurity 3Cat. No. P-L027-004No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.